NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression
- Authors
- Kim, Aeyung; Yang, Young; Lee, Myeong-Sok; Yoo, Young Do; Lee, Hee Gu; Lim, Jong-Seok
- Issue Date
- Dec-2008
- Publisher
- WILEY
- Keywords
- NDRG2; Melanogenesis; cAMP; TCF; beta-catenin; Mitf
- Citation
- PIGMENT CELL & MELANOMA RESEARCH, v.21, no.6, pp 653 - 664
- Pages
- 12
- Journal Title
- PIGMENT CELL & MELANOMA RESEARCH
- Volume
- 21
- Number
- 6
- Start Page
- 653
- End Page
- 664
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/14145
- DOI
- 10.1111/j.1755-148X.2008.00503.x
- ISSN
- 1755-1471
1755-148X
- Abstract
- NDRG2 (N-myc downstream-regulated gene 2) is a candidate tumor suppressor implicated in control of glioblastoma proliferation and dendritic cell differentiation. The microphthalmia-associated transcription factor (Mitf) plays a crucial role in the melanocyte lineage and in melanoma by controlling survival, differentiation, cell cycle entry and exit, and melanoma metastasis. Identifying upstream regulators of Mitf expression, therefore, remains a key issue. In this study, we aimed to assess whether the candidate tumor suppressor NDRG2 can modulate Mitf expression. Here, we show that NDRG2 acts to prevent cAMP and beta-catenin-mediated activation of the Mitf promoter, thereby blocking melanogenesis via the downstream Mitf target genes Tyrosinase, Tyrp1 and Dct. The data suggest that NDRG2 impairs melanogenesis by interfering with both the TCF/beta-catenin and cAMP/CREB pathways that are known to stimulate Mitf expression in melanocytes and have major implications for the role of NDRG2 in pigmentation and melanoma progression. Taken together, the results not only identify NDRG2 as a novel regulator of pigmentation, but also potentially a key factor in regulating melanoma progression via Mitf.
- Files in This Item
-
Go to Link
- Appears in
Collections - 이과대학 > 생명시스템학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.